Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release

Madhukar H. Trivedi, David L. Dunner, Susan G. Kornstein, Michael E. Thase, John M. Zajecka, Anthony J. Rothschild, Edward S. Friedman, Richard C. Shelton, Martin B. Keller, James H. Kocsis, Alan Gelenberg

Research output: Contribution to journalArticle

29 Scopus citations

Abstract

Background: Psychosocial outcomes from the Prevention of Recurrent Episodes of Depression with Venlafaxine ER for Two Years (PREVENT) study were evaluated. Methods: Adult outpatients with recurrent major depressive disorder (MDD) and response or remission following 6-month continuation treatment with venlafaxine extended release (ER) were randomized to receive venlafaxine ER or placebo for 1 year. Patients without recurrence on venlafaxine ER during year 1 were randomized to venlafaxine ER or placebo for year 2. Psychosocial functioning was assessed using the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q), Life Enjoyment Scale-Short Version (LES-S), Social Adjustment Scale-Self-Report (SAS-SR) total and individual factors, Short Form Health Survey (SF-36) (vitality, social functioning, and role function-emotional items), and Longitudinal Interval Follow-up Evaluation (LIFE). Results: At year 1 end, better overall psychosocial functioning was seen among patients randomly assigned to venlafaxine ER (n = 129) vs placebo (n = 129), with significant differences at end point on SF-36 role function-emotional, Q-LES-Q, and SAS-SR total, and work, house work, social/leisure, and extended-family factor scores (p ≤ 0.05). At year 2 end, significant differences favored venlafaxine ER (n = 43) vs placebo (n = 40) on SF-36 vitality and role function-emotional, Q-LES-Q, LES-S, LIFE, and SAS-SR total, social/leisure, and extended-family factor scores (p ≤ 0.05). Limitations: Patients with chronic MDD or treatment resistance were excluded and long-term specialist care was a financial incentive for treatment compliance. Discontinuation-related adverse events may have compromised the integrity of the treatment blind. Conclusions: For patients with recurrent MDD, 2 years' maintenance therapy with venlafaxine ER may improve psychosocial functioning vs placebo.

Original languageEnglish (US)
Pages (from-to)420-429
Number of pages10
JournalJournal of affective disorders
Volume126
Issue number3
DOIs
StatePublished - Nov 2010

Keywords

  • Maintenance treatment
  • Major depressive disorder
  • Psychosocial outcomes
  • Venlafaxine extended release

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release'. Together they form a unique fingerprint.

  • Cite this

    Trivedi, M. H., Dunner, D. L., Kornstein, S. G., Thase, M. E., Zajecka, J. M., Rothschild, A. J., Friedman, E. S., Shelton, R. C., Keller, M. B., Kocsis, J. H., & Gelenberg, A. (2010). Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. Journal of affective disorders, 126(3), 420-429. https://doi.org/10.1016/j.jad.2010.04.011